Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 4/20 | 0.74 |
| ▸ | CA1 | P00915 | 4/20 | 0.74 |
| ▸ | CA2 | P00918 | 4/20 | 0.74 |
| ▸ | CA4 | P22748 | 4/20 | 0.74 |
| ▸ | CA5A | P35218 | 4/20 | 0.74 |
| ▸ | CA7 | P43166 | 4/20 | 0.74 |
| ▸ | CA9 | Q16790 | 4/20 | 0.74 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.74 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.74 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.54 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985757 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL21874406 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL13534110 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL14531064 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL3161959 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL8520095 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL654710 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL16876701 | 0.77 | SMN1; SMN2 (0.63) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL5561697 | 0.77 | SMN1; SMN2 (0.63) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL16876699 | 0.77 | SMN1; SMN2 (0.63) | SMN1; SMN2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278929-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278929-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278929-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2016-03-08 | — | — | US | disclosed |
| US-8742111-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742111-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742111-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-06-03 | — | — | US | disclosed |
| US-20080319196-A1 | Process for Synthesizing Remifentanil | MALLINCKRODT INC. | 2008-12-25 | — | — | US | disclosed |
| WO-2007061555-A1 | PROCESS FOR SYNTHESIZING REMIFENTANIL | MALLINCKRODT INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-5843900-A | Bradykinin antagonists | CORTECH, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| US-5126455-A | Preparation of substituted alkali metal piperidine-4-carboxylates | GLAXO INC. (US) | 1992-06-30 | — | — | US | disclosed |
| US-5106983-A | Process of making carfentanil and related analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-04-21 | — | — | US | disclosed |
| US-5039804-A | Hydrolysis of 1,3,8,-triazaspiro 4.5!decane-2,4-diones, chemical intermediates for opium type analgesics | GLAXO INC. (US) | 1991-08-13 | — | — | US | disclosed |
| EP-0433048-A1 | Preparation of substituted alkali metal piperidine-4-carboxylates | GLAXO WELLCOME INC. (US) | 1991-06-19 | — | — | EP | disclosed |
| US-4179569-A | ANALGESIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319196-A1 | Process for Synthesizing Remifentanil | OPRK1, OPRM1, OGFR | SMN1; SMN2 840/4885CA12 2311/4885CA1 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.